HP cohorts, MAD
SAD
Open-label, repeat doses of ARO-ANG3 demonstrated changes in most pharmacodynamic parameters similar to single-dose ARO-ANG3. The HP MAD cohorts were not placebo controlled. However, given similarities between the HP SAD and MAD cohorts, data pooled from the placebo groups in the SAD cohorts were compared to results from the MAD HPs.Dosing with ARO-ANG3 reduced ANGPTL3 concentrations beginning at day 3. Reduction occurred in a dose-dependent manner, with mean (s.d.) percentage change from baseline at day 113 ranging from −64.4% (19.3%) to −92.7% (4.3%) for 100 mg and 300 mg, respectively, compared to an increase of 25.0% (36.8%) for the SAD pooled placebo (Extended Data Fig. 